OPK

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside

On July 27, OPKO Health, Inc. released its Q2 numbers. So, OPK's revenue from transfer of IP and other increased 208% YoY to $46.1 million in Q2, driven by a Nicoya license amendment. Also, OPKO raised its full-year 2026 revenue guidance from $530-$560 million to $560-$585 million.

OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.

OPKO Health, Inc. (OPK) Q2 2026 Earnings Call Transcript

MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business highlights and financial results for the second quarter ended June 30, 2026. Highlights from the second quarter of 2026 and recent weeks included the following: ModeX presented data on multispecific antibody targeted in vivo CAR T cell programs at the American Society of Gene + Cell Therapy (ASGCT) Annual Meeting, with plans to enter Phase 1 studies later this year or in early 2027.

OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.

MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting. The poster, “Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly,” available here, was presented by Moran Golan, Ph.D., Director of Preclinical & Clinical Pharmacology at OPKO Biologics.